Human Immunodeficiency Virus Protease Inhibitors

Bibliography

• BARRÉ-SINOUSSI F, CHERMANN JC, KEY F, et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220:868–871.
   PubMed Web of Science ®Google Scholar
• The first report of isolation of a previously unknown retrovirus from a lymph node of a patient with symptoms that precede AIDS.
   Google Scholar
• POPOVIC M, SARNGADHARAN MG, READ E, GALLO RC: Detection and continuous production of cytopathic retroviruses (HTLV-I11) from patients with AIDS and pre-AIDS. Science (1984) 224:497–500.
   PubMed Web of Science ®Google Scholar
• GALLO RC, SALAHUDDIN SZ, POPOVICM et al. : Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk of AIDS. Science (1984) 224:500–503.
   PubMed Web of Science ®Google Scholar
• CLAVEL F, GUETARD D, BRUN-VEZINET F, et al.: Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 233:343–346.
   PubMed Web of Science ®Google Scholar
• MITSUYA H, YARCHOAN R, BRODER S: Molecular targets for AIDS therapy. Science (1990) 249:1533–1543.
   PubMed Web of Science ®Google Scholar
• An excellent review of potential molecular targets.
   Google Scholar
• KOHL NE, EMINI EA, SCHLIEF WA, et al.: Active human deficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA (1988) 85:4686–4690.
   PubMed Web of Science ®Google Scholar
• The first demonstration that HIV protease is essential for production of infectious virus.
   Google Scholar
• GOTTLINGER HG, SODROSKI JG, HASELTINE WA: Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA (1989) 86:5781–5785.
   PubMed Web of Science ®Google Scholar
• PENG C, HO BK, CHANG TW, CHANG NT: Role of human immunodeficiency virus type 1-specific protease in core protein maturation and infectivity. J. Virol. (1989) 63:2550–2556.
   PubMed Web of Science ®Google Scholar
• BLAXTER M: Economic costs. In: AIDS: Worldwide Policies and Problems. Office of Health Economics, London (1991 ):17–18.
   Google Scholar
• LALEZARI J, HAUBRICH R, BURGER HU, et al. AND THE NV14256 STUDY TEAM: Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase®, SQV) plus Hivid (Zalcitabine, ddC). 11th Int. Conf. AIDS. Vancouver (1996). Abstract LB.B.6033.
   Google Scholar
• CAMERON DW, HEATH-CHIOZZI M, KRAVCIK S, et al. THE ADVANCED HIV RITONAVIR STUDY GROUP, LEONARD J: Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: an update. 11th Int. Conf. AIDS. Vancouver (1996). Abstract Mo.B.411.
   Google Scholar
• TESTA MA, LENDERKING WR, FISCHER L, REVICKI DA, COLLIER AC: Effects of combina-tion therapy with saquinavir, zidovudine and zalcitabine on quality of life. I I th Int. Conf. AIDS. Vancouver (1996). Abstract Tu.B.542.
   Google Scholar
• NABULSI A, REVICKI D, CONWAY D, et al.: Quality of life consequences of adding ritonavir to current antiviral therapy for advanced HIV patients. 11th Int. Conf. AIDS. Vancouver (1996). Abstract LB.B.6046.
   Google Scholar
• MORAN N: WHO issues another gloomy tuberculosis report. Nature Medicine (1996) 2:377.
   PubMed Web of Science ®Google Scholar
• STONED: HIV protease inhibitors head to market. Biotechnology (1995) 13:940–942.
   PubMedGoogle Scholar
• AZT combination trial shows positive results. Nature (1995) 377:277.
   Google Scholar
• BARTLETT MG: Zidovudine now or later New Engl. J Med. (1993) 329:351–352.
   Google Scholar
• ABOULKER J-P, SWART AM: Preliminary analysis of the Concorde trial. Lancet (1993) 341:889–890.
   PubMed Web of Science ®Google Scholar
• VOLBERDING PA, LAGAKOS SW, GRIMES JM, et al.: A comparison of immediate with deferredzidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. New Engl. I Med. (1995) 333:401–407.
   PubMed Web of Science ®Google Scholar
• COOPER DA, GATELL JM, KROON S, et al. AND THE EUROPEAN-AUSTRALIAN COLLABO-RATIVE GROUP: Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. New Engl. I Med. (1993) 329:297–303.
   PubMed Web of Science ®Google Scholar
• KINLOCH-DE LOES S, HIRSCHEL BJ, HOEN B et al: A controlled trial of zidovudine in primary human immunodeficiency virus infection. New Engl. I Med. (1995) 333:408–413.
   PubMed Web of Science ®Google Scholar
• ABER V, ABOULKER J-P, BABIKER AG, et al.: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet (1996) 348:283–291.
   PubMed Web of Science ®Google Scholar
• ERON JJ, BENOIT SL, JEMSEK J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New Engl. I Med. (1995) 333:1662–1669.
   PubMed Web of Science ®Google Scholar
• BARUCH A, MASTRODONATO-DELORA P, SCHNIPPER E, SALGO M: Efficacy and safety of triple combination therapy with invirase (saquinavir/SQV/HIV protease inhibitor), epivir (3TC/lamivudine) and retrovir® (ZDV/zidovudine) in HIV-infected patients. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.172.
   Google Scholar
• MARKOWITZ M, CAO Y, HURLEY A, et al.: Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. 11th Int. Conf AIDS. Vancouver (1996). Abstract Th.B.933.
   Google Scholar
• GULICK R, MELLORS J, HAVLIR D, et al.: Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). 11th Int Conf AIDS. Vancouver (1996). Abstract Th.B.931.
   Google Scholar
• STYRT BA, PIAZZA-HEPP TD, CHIKAMI GK: Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Res. (1996) 31:121–135.
   PubMed Web of Science ®Google Scholar
• VAN LEEUVVEN R, VAN DER HURK PJ, JOBSIS GJ et al.: Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection. Genitourin. Med. (1990) 66:418–422.
   PubMedGoogle Scholar
• RICHMAN DD, FISCHL MA, GRIECO MH, et al. AND THE AZT COLLABORATIVE WORKING GROUP: The toxicity of AZT in the treatment of AIDS and AIDS-related complex. New Engl. Med. (1987) 317:192–197.
   PubMed Web of Science ®Google Scholar
• YARCHOAN R, THOMAS RV, ALLAIN JP, et al.: Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus as a single agent and alternating with zidovudine, AZT. Lancet (1988) 1:76–80.
   PubMed Web of Science ®Google Scholar
• COOLEY TP, KUNCHES LM, SAUNDERS CA, et al.: Once daily administration of 2',3'-dideoxy-inosine, ddI, in patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a Phase I trial. New Engl. I Med. (1990) 322:1340–1345.
   PubMed Web of Science ®Google Scholar
• BROWNIE MJ, MAYER KB, CHAFFEE SBD, et al.: 2',3'-didehydro-3'-deoxythymidine, d4T, in patients with AIDS or AIDS-related complex: a Phase I trial. I Infect. Dis. (1993) 167:21–29.
   Google Scholar
• PLUDA JM, COOLEY TP, MONTANER JSG, et al.: A Phase I-II study of 2'-deoxy -3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. I Infect. Dis. (1995) 171:1438–1447.
   Google Scholar
• LEWIS LL, VENZON D, CHURCH J, et al. THE NATIONAL CANCER INSTITUTE PEDIATRIC BRANCH HUMAN IMMUNODEFICIENCY VIRUS WORKING GROUP: Lamivudine in children with human immunodeficiency virus infection: a Phase I/II study. I Infect. Dis. (1996) 174:16–25.
   PubMed Web of Science ®Google Scholar
• LARDER BA, DARBY G, RICHMAN DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 243:1731–1734.
   PubMed Web of Science ®Google Scholar
• REICHMAN RC, TEJANI N, LAMBERT JL, et al.: Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI. Antiviral Res. (1993) 20:267–277.
   PubMed Web of Science ®Google Scholar
• FITZGIBBON JE, HOWELL RM, HABERZETTL CA, et al.: Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob. Agents Chemother. (1992) 36:153–157.
   PubMed Web of Science ®Google Scholar
• LIN PF, SAMANTA H, ROSE RE, et al.: Genotypic and phenotypic analysis of human immunode-ficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis . (1994) 170:1157–1164.
   PubMed Web of Science ®Google Scholar
• SCHUURMAN R, NUHUIS M, VAN LEEUVVEN R, et al.: Rapid changes in human immunodefi-ciency virus type 1 RNA load and appearance of drug-resistant populations in persons treated with lamivudine (3TC). J. Infect. Dis. (1995) 171:1411–1419.
   PubMed Web of Science ®Google Scholar
• World Health Organisation Weekly Epidemiological Record (1996) 71:205–212.
   Google Scholar
• Global Program on AIDS: The Current Global Situation on the HIV/AIDS Pandemic. World Health Organization (15 December 1995).
   Google Scholar
• Health and Personal Social Services Statistics for England (1995 Edition).
   Google Scholar
• Alarm at funding cuts. AIDS Newsletter (1996) 11(6):8.
   Google Scholar
• REVETS H, MARISSENS D, DE WIT S, et al.: Comparative evaluation of NASBA HIV-1 RNA QT, Amplicor HIV monitor, and Quantiplex HIV RNA assay, three methods for quantification of human immunodeficiency virus type! RNA in plasma. J. Clin. Microbiol. (1996) 34:1058–1064.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses (1992) 8:119–134.
   PubMed Web of Science ®Google Scholar
• TANTILLO C, DING J, JACOBO-MOLINA A, et al.: Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance. J. MoL Biol. (1994) 243:369–387.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD, HAVLIR D, CORBEIL J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. (1994) 68:1660–1666.
   PubMed Web of Science ®Google Scholar
• KING E: What are NNRTIs AIDS Treatment Update (1996) 43:3.
   Google Scholar
• DAAR ES, LI XL, MOUDGIL T, HO DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA (1990) 87:6574–6578.
   PubMed Web of Science ®Google Scholar
• BLACK, PL, WOOD O, BROUD D, et al.: T-20, a novel inhibitor of HIV-1 fusion, blocks recovery of infectious HIV-1 and inhibits viral load in vivo in the HuPBMC-SCID mouse model. 1 1 th Int. Conf AIDS. Vancouver (1996). Abstract Tu.A.263.
   Google Scholar
• HSU M-C, SCHUTT AD, HOLLY M, et al.: Inhibition of HIV replication in acute and chronic infections in vitro by a tat antagonist. Science (1991) 254:1799–1802.
   PubMed Web of Science ®Google Scholar
• FISHER AG, FEINBERG MB, JOSEPHS SF, et al.: The trans-activator gene of HTLV-Ill is essential for virus replication. Nature (1986) 320:367–371.
   PubMed Web of Science ®Google Scholar
• TAM S, BORGESE J, CISLO A, et al.: Tat inhibitors: a new class of anti-HIV agents. Spec. PubL - R. Soc. Chem. (1993) 119(Recent Advances in the Chemistry of Anti-infective Agents):314–321.
   Google Scholar
• CONNELL EV, HSU MC, RICHMAN DD: Combinative interactions of a human immunodefi-ciency virus (HIV) tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. Antimicrob. Agents Chemother. (1994) 38:348–352.
   PubMed Web of Science ®Google Scholar
• HAUBRICH RH, FLEXNER C, LEDERMAN MM, et al. AND THE AIDS CLINICAL TRIALS GROUP 213 TEAM: A randomized trial of the activity and safety of Ro 24-7429 (tat antagonist) versus nucleoside for human immunodeficiency virus infection. I Infect. Dis. (1995) 172:1246–1252.
   PubMed Web of Science ®Google Scholar
• RICE P, CRAIGIE R, DAVIES DR: Retroviral integrases and their cousins. Curr. Opin. StrucL Biol. (1996) 6:76–83.
   PubMed Web of Science ®Google Scholar
• VINK C, RONALD HA: The human immunodeficiency virus integrase protein. Trends Genet. (1993) 9:433–437.
   PubMed Web of Science ®Google Scholar
• MAZUMDER A, NEAMATI N, OJVVANG JO, et al.: Inhibition of the human immunodeficiency virus type! integrase by guanosine quartet structures. Biochem. (1996) 35:13762–13771.
   PubMed Web of Science ®Google Scholar
• ROBINSON EW, Jr., REINECKE MG, ABDEL-MALEK S, JIA Q, CHOW SA: Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. USA (1996) 93:6326–6331.
   PubMed Web of Science ®Google Scholar
• BURKE TR, Jr., FESEN MR, MAZUMDER A, et al.: Hydroxylated aromatic inhibitors of integrase. Med. Chem. (1995) 38:4171–4178.
   Web of Science ®Google Scholar
• HAZUDA D, BLAU C, FELOCK P, et al.: Isolation and characterisation of a novel class of human immunodeficiency virus integrase inhibitors from natural product screening. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.A.1020.
   Google Scholar
• RATNER L: Glucosidase inhibitors for treatment of HIV-1 infection. AIDS Res. Human Retroviruses (1992) 8:165–173.
   PubMed Web of Science ®Google Scholar
• JACOB GS, BRYANT ML: Iminosugar glycosylation inhibitors as anti-HIV agents. PerspecL Drug Discovery Res. (1993) 1:211–224.
   Google Scholar
• TIERNY M, POTTAGE J, KESSLER H, et al. FOR THE AIDS CLINICAL TRIALS GROUP (ACTG) OF THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES: The tolerability and pharmacokinetics of N-butyl-nojirimycin in patients with advanced HIV disease (ACTG 100). 1 Acquir. Immune Defic. Syndr. Hum. RetroviroL (1995) 10:549–553.
   PubMed Web of Science ®Google Scholar
• GORELICK RJ, CHABOT DL, REIN A, HENDERSON LE, ARTHUR LO: The two zinc fingers in the human immunodeficiency virus type 1 nudeocapsid protein are not functionally equivalent. I ViroL (1993) 67:4027–4036.
   PubMed Web of Science ®Google Scholar
• RICE WG, SCHAEFFER CA, HARTEN B, et al.: Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds. Nature (1993) 361:473–475.
   PubMed Web of Science ®Google Scholar
• RICE WG, SCHAEFFER CA, GRAHAM L, et al.: The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. Proc. Natl. Acad. Sci. USA (1993) 90:9721–9724.
   PubMed Web of Science ®Google Scholar
• BUNNELL BA, MORGAN RA: Gene therapy for HIV infection. Drugs Today (1996) 32:209–224.
   Web of Science ®Google Scholar
• LISZIEWICZ J, SUN D, WEICHOLD FF, et al.: Antisense oligodeoxynudeotide phosphorothioate complementary to gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc. Natl. Acad. Sci. USA (1994) 91:7942–7946.
   PubMed Web of Science ®Google Scholar
• ZHANG R, YAN J, SHAHINIAN H, et al.: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynudeotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. (St Louis) (1995) 58:44–53.
   PubMed Web of Science ®Google Scholar
• BLOOM BR: A perspective on AIDS vaccines. Science (1996) 272:1888–1890.
   PubMed Web of Science ®Google Scholar
• DOLIN R: Human studies in the development of human immunodeficiency virus vaccines. J. Infect. Dis. (1995) 172:1175–1183.
   PubMed Web of Science ®Google Scholar
• RATNER L, HASELTINE W, PATARCA R, et al.: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 313:277–284.
   PubMed Web of Science ®Google Scholar
• HELLEN CUT, KRAUSSLICH H-G, WIMMER E: Proteolytic processing of polyproteins in the replication of RNA viruses. Biochemistry (1989) 28:9881–9890.
   PubMed Web of Science ®Google Scholar
• LE GRICE SFJ, MILLS J, MOUS J: Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J. (1988) 7:2547–2553.
   PubMed Web of Science ®Google Scholar
• PEARL LH, TAYLOR WR: A structural model for the retroviral proteases. Nature (1987) 329:351–354.
   PubMed Web of Science ®Google Scholar
• The first suggestion that HIV protease functions as a dimer, and construction of a molecular model.
   Google Scholar
• KATOH I, YASUNAGA T, IKAWA Y, YOSHINAKA Y: Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor. Nature (1987) 329:654–656.
   PubMed Web of Science ®Google Scholar
• DARKE PL, LEU C-T, DAVIS LJ, et al.: Human immunodeficiency virus protease. Bacterial expression and characterisation of the purified aspartic protease. I Biol. Chem. (1989) 264:2307–2312.
   Web of Science ®Google Scholar
• SEELMEIER S, SCHMIDT H, TURK V, VON DER HELM K: Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA (1988) 85:6612–6616.
   PubMed Web of Science ®Google Scholar
• LAPATTO P, BLUNDELL T, HEMMINGS A, et al.: X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature (1989) 342:299–302.
   PubMed Web of Science ®Google Scholar
• WLODAWER A, MILLER M, JASKOLSKI M, et al.: Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science (1989) 245:616–621.
   PubMed Web of Science ®Google Scholar
• NAVIA MA, FITZGERALD PMD, MCKEEVER BM, et al.: Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 337:615–620.
   PubMed Web of Science ®Google Scholar
• WLODAWER A, ERICKSON JVV: Structure-based inhibitors of HIV-1 protease. Ann. Rev. Biochem. (1993) 62:543–585.
   PubMed Web of Science ®Google Scholar
• TOMASSELLI AG, THAISRIVONGS S, HEINRIKSON RL: Discovery and design of HIV protease inhibitors as drugs for treatment of AIDS. Adv. Antiviral Drug Design (1996) 2:173–228.
   Google Scholar
• Choudhary MI (Ed.), Harwood Academic Publishers (1996):161–211.
   Google Scholar
• Ellis GP, Luscombe DK (Eds.), Elsevier (1995):239–287.
   Google Scholar
• MARTIN JA: Recent advances in the design of HIV proteinase inhibitors. Antiviral Res. (1992) 17:265–278.
   PubMed Web of Science ®Google Scholar
• MEEK TD: Inhibitors of HIV-1 protease. J. Enz. Inhib. (1992) 6:65–98.
   Google Scholar
• DEBOUCK C: The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Human Retroviruses (1992) 8:153–164.
   PubMed Web of Science ®Google Scholar
• HUFF JR: HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. (1991) 34:2305–2314.
   PubMed Web of Science ®Google Scholar
• NORBECK DW, KEMPF DJ: HIV protease inhibitors. Ann. Rep. Med. Chem. (1991) 26:141–150.
   Web of Science ®Google Scholar
• TOMASSELLI AG, HOWE WJ, SAWYER TX., WLODAWER A, HEINRIKSON RL: The complexi-ties of AIDS: an assessment of the HIV protease as a therapeutic target. Chimica Oggi (May 1991):6–27.
   Google Scholar
• WOLFENDEN R: Analog approaches to the structure of the transition state in enzyme reactions. Acc. Chem. Res. (1972) 5:10–18.
   Web of Science ®Google Scholar
• ROBERTS NA, MARTIN JA, KINCHINGTON D, et al.: Inhibitors of HIV proteinase. Science (1990) 248:358–361.
   PubMed Web of Science ®Google Scholar
• ERICKSON J, NIEDHART DJ, VANDRIE J, et al.: Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (1990) 249:527–533.
   PubMed Web of Science ®Google Scholar
• KEMPF DJ, NORBECK DW, CODACOVI L, et al.: Structure-based C2 symmetric inhibitors of HIV protease. J. Med. Chem. (1990) 33:2687–2689.
   PubMed Web of Science ®Google Scholar
• BONE R, VACCA JP, ANDERSON PS, HOLLOWAY MK: X-ray crystal structure of the HIV protease complex with L-700,417, an inhibitor with pseudo C2 symmetry.1 Am. Chem. Soc. (1991) 113:9382–9384.
   Web of Science ®Google Scholar
• KEMPF DJ, CODACOVI L, WANG XC, et al.: Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamimo-1,5-dipheny1-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. I Med. Chem. (1993) 36:320–330.
   Web of Science ®Google Scholar
• KITCHEN VS, SKINNER C, ARIYOSHI K, et al.: Safety and activity of saquinavir in HIV infection. Lancet (1995) 345:952–955.
   PubMed Web of Science ®Google Scholar
• SCHAPIRO JM, WIMTERS MA, STEWART F, et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. (1996) 124:1039–1050.
   PubMed Web of Science ®Google Scholar
• WORKMAN C, LEWIS C, SMITH DO: Resolution of Kaposi's sarcoma associated with saquinavir therapy - case report. 11th Int Conf AIDS. Vancouver (1996). Abstract Tu. B.2217.
   Google Scholar
• AIDS Treatment Update (May 1996) 41.
   Google Scholar
• DANNER SA, CARR A, LEONARD JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. New Engl. J. Med. (1995) 333:1528–1533.
   PubMed Web of Science ®Google Scholar
• HICK CB, LEHMAN L, ERON JJ, et al.: Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses. 11th Int. Conf. AIDS. Vancouver (1996) Abstract Mo.B.415.
   Google Scholar
• HSU A, GRANNEMAN GR, SUN E, et al.: Assessment of single- and multiple-dose interactions between ritonavir and saquinavir. 11th Int. Conf. AIDS. Vancouver (1996). Abstract LB.B.6041.
   Google Scholar
• CAMERON W, SUN E, MARKOWITZ M, et al.: Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. 11th Int. Conf. AIDS. Vancouver (1996). Abstract Th.B.934.
   Google Scholar
• HIRSCHEL BJ, RUTSCHMANN 0, FATHI M, et al.: Treatment of advanced HIV infections with ritonavir plus saquinavir. 11th Int. Conf. AIDS. Vancouver (1996). Abstract LB.B.6030.
   Google Scholar
• CAMERON DW, HSU H, GRANNEMAN GR, et al.: Pharmacokinetics of ritonavir-saquinavir combination therapy. AIDS (1996) 10\(Suppl. 2):555.6.
   PubMedGoogle Scholar
• MELLORS J, STEIGBIGEL R, GULICK R, FRANK I: A randomised double-blind study of the HIV protease inhibitor L-735,524 vs. Zidovudine (ZDV) in p24 antigenemic, HIV-1 infected patients with less than 500 CD4 cells/mm3. Int. Conf Retroviruses Opportunistic Infect. (1995).
   Google Scholar
• STEIGBIGEL R, BERRY P, TEPPLER H, et al.: Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 g/d) 1000 mg q8h (3.0 g/d) and 800 mg q6h (3.2 g/d). 1 1 th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.412.
   Google Scholar
• MULDER J, MCKINNEY N, CHRISTOPHERSON C, et al.: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. I Clin. Microbiol. (1994) 32:292–300.
   Web of Science ®Google Scholar
• PETO T: Surrogate markers in HIV disease. I Antimicrob. Chemother. (1996) 37(Suppl. B, HIV Infection):161–170.
   PubMed Web of Science ®Google Scholar
• MELLORS JW: Viral load and clinical outcome: a review of recent studies. 5th International Workshop on HIV Drug Resistance. Whistler, Canada (3–6 July 1996). Abstract 35.
   Google Scholar
• MOYLE GJ, YOULE M, HIGGS C, et al.: Extended follow-up of safety and efficacy of Agouron's HIV proteinase inhibitor AG1343 (Viracept®) in virological responders from the UK Phase I/11 dose finding study. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.173.
   Google Scholar
• HUMPHREY RW, NGUYEN B-Y, WYVILL KM, et al.: A Phase I trial of HIV protease inhibi-tor,KNI-272, in patients with AIDS or symptomatic HIV infection. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.1132.
   Google Scholar
• CONANT M, MARKOWITZ M, HURLEY A, et al.: A randomised Phase II dose range-finding study of the HIV protease inhibitor Viracept as monotherapy in HIV positive patients. 11th Int. Conf AIDS. Vancouver (1996). Abstract Tu.B.2129.
   Google Scholar
• RUTSCHMANN OT, KAISER L, GABRIEL V, et al.: Adding saquinavir to d4T in advanced HIV infection. 11th Int. Conf AIDS. Vancouver (1996). Abstract Th.B.945.
   Google Scholar
• MATHEZ D, BAGNARELLI P, DE TRUCHIS P, et al.: A triple combination of ritonavir + AZT + ddC as a first line treatment of patients with AIDS: update. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.175.
   Google Scholar
• GATHE J, Jr., BURKHARDT B, HAWLEY P, et al.: A randomised Phase II study of Viracept, a novel HIV protease inhibitor, used in combination with stavudine (D4T) vs. stavudine(D4T) alone. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.413.
   Google Scholar
• MARKOWITZ M, CAO Y, HURLEY A, et al.: Triple therapy with AZT and 3TC in combination with nelfinavir mesylate in 12 antiretroviral-naive subjects chronically infected with HIV-1. 11th Int. Conf AIDS. Vancouver (1996). Abstract LB.B.6031.
   Google Scholar
• WORKMAN C, DOWNIE J, SUTHERLAND D, et al.: Rapid viral load decrease in primary infection associated with aggressive therapy. 11th Int. Conf AIDS. Vancouver (1996). Abstract LB.B. 6021.
   Google Scholar
• REEDIJK M, BOUCHER CAB, VAN BOMMEL T, et al.: Safety, pharmacokinetics and antiviralactivity of A77003, a C-2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. (1995) 39:1559–1564.
   PubMed Web of Science ®Google Scholar
• THE INDINAVIR (MK-639) PHARMACOKINETIC STUDY GROUP: Indinavir (MK-639) druginteraction studies. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.174.
   Google Scholar
• HSU A, GRANNEMAN GR, WITT G, CAVANAUGH JH, LEONARD J: Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. 11th Int. Conf. AIDS. Vancouver (1996). Abstract Mo.B.1200.
   Google Scholar
• BERTZ RJ, CAO G, CAVANAUGH JH, et al.: Effect of ritonavir on the pharmacokinetics of desipramine. 11th Int. Conf. AIDS. Vancouver (1996). Abstract Mo.B.1201.
   Google Scholar
• CATO A, CAVANAUGH JH, SHI H, et al.: Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. 11th Int. Conf. AIDS. Vancouver (1996). Abstract Mo.B.1119.
   Google Scholar
• SUN E, HEATH-CHIOZZI M, CAMERON DW, et al.: Concurrent ritonavir and rifabutin increases risk of rifabutin-associated side-effects. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.171.
   Google Scholar
• OUELLET D, HSU A, QIAN J, et al.: Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. 11th Int. Conf. AIDS. Vancouver (1996). Abstract Mo.B.1198.
   Google Scholar
• CAMERON DW, HSU H, GRANNEMAN GR, et al.: Pharmacokinetics of ritonavir-saquinavir combination therapy. AIDS (1996) 10\(Suppl. 2):SS5.6.
   Google Scholar
• PRESTON BD, POIESZ BJ, LOEB LA: Fidelity of HIV-1 reverse transcriptase. Science (1988) 242:1168–1171.
   PubMed Web of Science ®Google Scholar
• CRAIG JC, WHITTAKER L, DUNCAN IB, ROBERTS NA: In vitro resistance to an inhibitor of HIV proteinase (Ro31-8959) relative to inhibitors of reverse transcriptase (AZT and TIBO). Antiviral Chem. Chemother. (1993) 4:335–339.
   Web of Science ®Google Scholar
• JACOBSEN H, YASARGIL K, WINSLOW DL, et al.: Characterisation of human immunodefi-ciency virus type! mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology (1994) 206:527–534.
   Web of Science ®Google Scholar
• MARKOWITZ M, HONGMEI M, KEMPF DJ, et al.: Selection and analysis of human immunode-ficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. ViroL (1995) 69:701–706.
   PubMed Web of Science ®Google Scholar
• TISDALE M, MYERS RE, MASCHERA B, et al.: Cross-resistance analysis of human immunode-ficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. (1995) 39:1704–1710.
   PubMed Web of Science ®Google Scholar
• GULNIK SV, SUVOROV LI, LIU B, et al.: Kinetic characterisation and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry (1995) 34:9282–9287.
   PubMed Web of Science ®Google Scholar
• PAZHANISAMY S, STUVER CM, CULLINAN AB, et al.: Kinetic characterisation of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. (1996) 271:17979–17985.
   PubMed Web of Science ®Google Scholar
• PARTALEDIS JA, YAMAGUCHI K, TISDALE M, et al.: In vitro selection and characterisation of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethy-lamino sulphonamide inhibitors of HIV-1 aspartyl protease. J. ViroL (1995) 69:5228–5235.
   PubMed Web of Science ®Google Scholar
• TISDALE M, MYERS R, NAJERA I et al.: Analysis of resistance interactions with 141W94 (VX-478) and other HIV-1 protease inhibitors. 5th International Workshop on HIV Drug Resistance. Whistler, Canada (3–6 July 1996):27.
   Google Scholar
• JACOBSEN H, HAENGGI M, OTT M, et al.: Reduced sensitivity to saquinavir: an update on genotyping from Phase I/II trials. Antiviral Res. (1996) 29:95–97.
   PubMed Web of Science ®Google Scholar
• MOLLA A, KORNEYEVA M, GAO Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine (1996) 2:760–766.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, SCHLEIF WA, BLAHY OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 374:569–571.
   PubMed Web of Science ®Google Scholar
• PATICK AK, DURAN M, CAO Y et al.: Genotypic and phenotypic characterisation of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. 5th International Workshop on HIV Drug Resistance. Whistler, Canada (3–6 July 1996):29.
   Google Scholar
• YAMADA A, ANDERSON B, KAGEYAMA S, et al.: Detection of mutations conferring on HIV drug resistance in patients receiving ICNI-272. 11th InL Conf AIDS. Vancouver (1996). Abstract Th.B.4346.
   Google Scholar
• RACE E, GILBERT SM, TOMLINSON PW, et al.: Long term treatment with saquinavir (Invirase) does not lead to a significant reduction in sensitivity to MK-639. I I th Int. Conf AIDS. Vancouver (1996). Abstract Tu.B.2124.
   Google Scholar
• CRAIG JC, DUNCAN 113, GILBERT S, et al.: Treatment with saquinavir (Invirase®) should leave the majority of patients with the option to use other HIV proteinase inhibitors. 5th International Workshop on HIV Drug Resistance. Whistler, Canada (3–6 July 1996):32.
   Google Scholar
• SCHMIT J-C, RUIZ L, CLOTET B, et al.: Resistance-related mutations in the HP/-1 protease gene of patients for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (London) (1996) 10:995–999.
   PubMed Web of Science ®Google Scholar
• CONDRA JII, HOLDER DJ, SCHLEIF WA, et al.: Bi-directional inhibition of HIV-1 drug resis-tance selection by combination therapy with indinavir and reverse transcriptase inhibitors. 11th Int. Conf AIDS. Vancouver (1996). Abstract Th.B.932.
   Google Scholar
• KOREYEVA M, MOLLA A, KEMPF D, et al.: Clinical and virological responses to ritonavir, an inhibitor of HIV protease. 11th Int. Conf AIDS. Vancouver (1996). Abstract Mo.B.1137.
   Google Scholar
• EMINI EA, CONDRA JH, SCHLEIF WA, et al.: Maintenance of long-term virus suppression in patients treated with the HP/-1 protease inhibitor Crixivan® (indinavir). I I th Int. Conf. AIDS. Vancouver (1996). Abstract Mo.B.170.
   Google Scholar
• MOLLA A, KEMPF D, KORNEYEVA M, et al.: Characterisation of the in vivo resistance pathway and pharmacokinetic properties of ritonavir. 5th International Workshop on HIV Drug Resistance. Whistler, Canada (3–6 July 1996):31.
   Google Scholar
• MELLORS JW, KINGSLEY L, GUPTA P, et al.: Prognostic value of plasma HP/-1 RNA quantifi-cation in seropositive adult men. 11th Int. Conf. AIDS. Vancouver (1996). Abstract We.B.410.
   Google Scholar
• O'BRIEN TR, BLATTNER WA, KRONER BL, GOEDERT JJ: HP/-1 RNA levels in early chronic infection: association with AIDS and long-term non-progression. 11th Int. Conf. AIDS. Vancouver (1996). Abstract Mo. C.323.
   Google Scholar
• VACCA JP, DORSEY BD, SCHLEIF WA, et al.: L-735,524, An orally bioavailable human immunodeficiency virus type-1 protease inhibitor. Proc. Natl. Acad. Sci. USA (1994) 91:4096–4100.
   PubMed Web of Science ®Google Scholar
• PERELSON AS, ESSUNGER P, MARKOWITZ M, HO DD: How long should treatment be given if we had an antiretroviral regimen that completely blocks HIV replication 11th InL Conf. AIDS. Vancouver (1996). Abstract Th.B.930.
   Google Scholar